• Risk-Sharing Agreement on the Pricing and Reimbursement of New Drugs

• Park Sylvia

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 125 ~ 153

• The Determinants of Pharmaceutical Firm¡¯s Research and Development Expenditures : Evidence from Kor...

• Kim Dong-Hwan

• Song Hyun-Jong, Jang Sun-Mee

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 101 ~ 123

• A study of identifying factors affecting cost-effectiveness threshold calculation in Korea

• Kim Youn-Hee

• Bae Eun-Young, Shin Sang-Jin, Park Sun-Young, Song Hyun-Jin, Park Joo-Yeon, Ahn Jeong-Hoon

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 79 ~ 100

• Cost-effectiveness analysis of antidepressants in treatment of major depressive disorder

• Park Jeong-Ae

• Choi Sang-Eun

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 57 ~ 77

• Income-related inequality in medical care utilization by provider types

• Rhim Kook-Hwan

• Lee Jun-Hyup

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 39 ~ 56

• Issues with Orphan Drug Pricing in South Korea

• Kwon Hye-Young

• Yang Bong-Min

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 17 ~ 37

• The effect of private health insurance on medical use

• Lee Chang-Woo

• Korean Journal of Health Economics and Policy   2010  Volume.16  No.2 1 ~ 15